Published Journal Articles
2024
Sigma-1 Receptor as a Novel Therapeutic Target in Diabetic Kidney Disease
2024-12
International Journal of Molecular Sciences (Issue : 24) (Volume : 25)
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease. Current treatments for DKD do not halt renal injury progression, highlighting an urgent need for therapies targeting key disease mechanisms. Our previous studies demonstrated that activating the Sigma-1 receptor (S1R) with fluvoxamine (FLU) protects against acute kidney injury by inhibiting inflammation and ameliorating the effect of hypoxia. Based on these, we hypothesized that FLU might exert a similar protective effect in DKD. Diabetes was induced in male Wistar rats using streptozotocin, followed by a seven-week FLU treatment. Metabolic and renal parameters were assessed along with a histological analysis of glomerular damage and fibrosis. The effects of FLU on inflammation, hypoxia, and fibrosis were tested in human proximal tubular cells and normal rat kidney fibroblasts. FLU improved renal function and reduced glomerular damage and tubulointerstitial fibrosis. It also mitigated inflammation by reducing TLR4, IL6, and NFKB1 expressions and moderated the cellular response to tubular hypoxia. Additionally, FLU suppressed TGF-β1-induced fibrotic processes and fibroblast transformation. These findings suggest that S1R activation can slow DKD progression and protect renal function by modulating critical inflammatory, hypoxic, and fibrotic pathways; therefore, it might serve as a promising novel drug target for preventing DKD.
2023
Cardioprotective and antifibrotic effects of low-dose renin–angiotensin–aldosterone system inhibitors in type 1 diabetic rat model
2023-12
International Journal of Molecular Sciences (Issue : 23) (Volume : 24)
Diabetic cardiovascular complications are associated with up to 50% mortality, and current therapies are not effective enough. Renin–angiotensin–aldosterone system inhibitors (RAASis) are the standard of care for diabetic patients with hypertension and albuminuria. Based on our previous studies reporting the renoprotective effects of low-dose RAASis, here, we hypothesized that low-dose RAASi treatment has cardioprotective and antifibrotic benefits in type 1 diabetes mellitus (T1DM). After five weeks of T1DM, adult male Wistar rats received low doses of ramipril, losartan, or eplerenone for two weeks. Heart rate, blood pressure, and pulse wave velocity (PWV) were recorded. Aortic intima–media thickness (IMT), collagen accumulation, and myocardial fibrosis were assessed. All RAASis reduced PWV elevation, prevented the progression of myocardial fibrosis, and normalized B-type natriuretic peptide, troponin I, and fibroblast growth factor 23 levels without affecting blood pressure. Interestingly, only eplerenone reversed the decline in Klotho levels and reduced IMT and fibrosis in the media of the aorta. Our comparative analysis suggests that mineralocorticoid receptor antagonists, particularly eplerenone, may offer superior efficacy in halting both the arterial and the myocardial injuries in T1DM compared to angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers.
2022
SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes
2022-02
PLOS ONE (Issue : 2) (Volume : 17)
ntroduction
Cardiovascular disease (CVD) is two to five times more prevalent in diabetic patients and is the leading cause of death. Therefore, identification of novel therapeutic strategies that reduce the risk of CVD is a research priority. Clinical trials showed that reduction in the relative risk of heart failure by sodium-glucose cotransporter 2 inhibitors (SGLT2i) are partly beyond their glucose lowering effects, however, the molecular mechanisms are still elusive. Here we investigated the role of SGLT2i dapagliflozin (DAPA) in the prevention of diabetes-induced cardiovascular complications.
Methods
Type 1 diabetes was induced with streptozotocin (65 mg/bwkg, ip.) in adult, male Wistar rats. Following the onset of diabetes rats were treated for six weeks with DAPA (1 mg/bwkg/day, po.).
Results
DAPA decreased blood glucose levels (D: 37±2.7 vs. D+DAPA: 18±5.6 mmol/L; p<0.05) and prevented metabolic decline. Aortic intima-media thickening was mitigated by DAPA. DAPA abolished cardiac hypertrophy, and myocardial damage. Cardiac inflammation and fibrosis were also moderated after DAPA treatment.
Conclusions
These data support the preventive and protective role of SGLT2i in diabetes-associated cardiovascular disease. SGLT2i may provide novel therapeutic strategy to hinder the development of cardiovascular diseases in type 1 diabetes, thereby improve the outcomes.
2019
Isolation, Identification and Antifungal Susceptibility Testing of Candida Species from Dermatologic Specimens in Duhok Province
2019-09
ZANCO Journal of Pure and Applied Sciences (Issue : 31) (Volume : 4)
Candida species. is a member of the mucous membrane of the normal flora, gastrointestinal tract and skin. They are endogenous
opportunistic pathogens that cause secondary infections with underlying immunocompromised condition. Candidiasis is a
common fungal infection in human. This study was aimed to isolation and identification of Candida using germ tube,
chlamydospore formation, and chromogenic agar testes and to asses antifungal susceptibility to some isolates. A total of 180
samples of skin swabs and skin particles, nail and hair were collected from patients in Duhok Province Hospitals, outpatient and a
number of private clinic dermatologists in Duhok city. A Total of 63 Candida isolates was detected in this study. These isolates
were subjected to germ tube test, chlamydospores formation and inoculation on commercially available CHROMagar. Candida
albicans was the main yeast species isolated followed by C. krusei, C. tropicalis and C. glabrata CHROMO agar is a convenient
and very fast method of identifications of Candida species even in resources poor settings. The result of antifungal sensitivity test
revealed that itraconazole is the main active antifungal against all Candi
Back